Document:

Letter Agreement - LP Clover Limited

 Exhibit 10.3 
 EXECUTION COPY 
 LP Clover Limited 
 Par La Ville Place 
 14 Par-La-Ville Road 
 P.O. Box HM 2332 
 Hamilton HM JX, Bermuda 
  
 July 31, 2009 
 Glenn A. Oclassen, President 
 Transcept Pharmaceuticals, Inc. 
 1003 W. Cutting Blvd., Suite #110 
 Point Richmond, CA 94804 
 Dear Mr. Oclassen:

 This letter agreement sets out the understanding of the undersigned concerning a proposed license agreement between LP Clover
Limited or one of its affiliates (“Clover”) and Transcept Pharmaceuticals, Inc. (“Transcept”), under which Clover would receive an exclusive license to seek regulatory approval of and commercialize Intermezzo®
in the territory of Canada (the “Proposed Transaction”). Transcept has agreed to grant Clover (i) the exclusive right to review, study and determine, in Clover’s sole discretion, the feasibility of developing and
commercializing Intermezzo® in Canada, and (ii) the exclusive option to negotiate the Proposed Transaction with Transcept ((i) and (ii) collectively, the “Option”), subject to the terms and conditions set forth below.

 1) Clover will pursue the Proposed Transaction if, in its sole judgment, Clover determines that (i) [***] and (ii) [***]. If Clover
decides to pursue the Proposed Transaction and notifies Transcept of its decision in writing before the expiration of the Option Period (as defined below), then Clover and Transcept will negotiate in good faith to agree upon a non-binding term sheet
for the Proposed Transaction (the “Term Sheet”). Upon agreement of the Term Sheet, each party will request its counsel to begin working in good faith with the other party’s counsel as soon as reasonably practicable on the
definitive transaction agreement and related documents containing the terms set forth in the Term Sheet and such other provisions as are customary in transactions of this nature. If Clover decides not to pursue the Proposed Transaction before the
expiration of the Option Period, it shall confirm and notify Transcept of its decision in writing. Upon Transcept’s receipt of Clover’s written notification indicating that Clover has decided not to pursue the Proposed Transaction, the
Option shall automatically terminate and Transcept shall be permitted to negotiate a license agreement for Intermezzo® as it relates to the territory of Canada with another party. Upon the expiration or termination of the Option pursuant to the
terms of this letter agreement without the parties entering into a definitive transaction agreement in respect of the Proposed Transaction, a copy of the notice attached hereto as Exhibit A that has been duly executed by Clover’s
affiliate shall be delivered to Transcept. 
  
  
 [***] Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from this exhibit and have been filed
separately with the Securities and Exchange Commission. 

 2) The initial period of the Option shall be the [***] period beginning on the date of this letter
agreement (the “Initial Option Period”, and together with any Renewal Period as defined below, the “Option Period”). The Option will renew for [***] periods following the Initial Option Period (each, a
“Renewal Period”) if Clover pays the Option Fee (as defined below) prior to the expiry of the then-current Option Period. Clover shall be obligated to pay a fee of [***] to Transcept at the commencement of the Initial Option Period
and prior to the commencement of each Renewal Period, if any (the “Option Fee(s)”). Notwithstanding the foregoing, prior to the date that an affiliate of Clover gives Transcept notice of its acceptance of the United States New Drug
Application for Intermezzo® following such New Drug Application’s final approval by the United States Food and Drug Administration (the “NDA Acceptance Date”), the Option will automatically renew for successive Renewal
Periods on the [***] of the date of this letter agreement, unless the Option is terminated by Clover as set forth in paragraph 1, and no Option Fees shall be payable by Clover but instead shall accrue upon the commencement of each Option Period. All
accrued Option Fees shall be paid to Transcept within [***] after the NDA Acceptance Date. Transcept shall be required to negotiate the Proposed Transaction, if so requested by Clover, at any time during the Option Period, so long as Clover has paid
to Transcept the Option Fee(s) required to be paid to Transcept as of such time. For the avoidance of doubt, (i) if, (A) following the NDA Acceptance Date, Clover fails to pay the accrued Option Fee(s) required to be paid to Transcept by
the deadline set forth above and Clover does not make such payment within [***] of Clover receiving written notice from Transcept that Clover has failed to pay such Option Fee(s) by the deadline set forth above, or (B) after the NDA Acceptance
Date, Clover elects not to pay any subsequent yearly renewal Option Fee within [***] of Clover receiving written notice from Transcept that Clover has failed to pay such Option Fee, then the restrictions described in paragraph 5 below shall no
longer apply and Transcept shall be free to negotiate with third parties regarding the Proposed Transaction and to enter into a definitive agreement with one or more third parties with respect to the Proposed Transaction, (ii) no Option Fee(s)
will be paid to Transcept prior to the NDA Acceptance Date, and (iii) if the NDA Acceptance Date does not occur or the Option expires pursuant to paragraph 3 below prior to the NDA Acceptance Date, then Clover will not owe Transcept any accrued
Option Fee(s). 
 3) If, at any time after the date hereof, any license and collaboration agreement in respect of Intermezzo® between
Transcept and an affiliate of Clover in the United States expires or terminates, then the Option shall be terminable upon thirty (30) days’ prior written notice from Transcept to Clover. 
 4) On the date the approved NDA No. 22-328 for Intermezzo® is transferred to an affiliate of Clover (the “NDA Transfer Date”),
Transcept shall assign or cause its affiliates to assign to Clover or Clover’s designee, the mark “INTERMEZZOTM”, together with any registrations or applications for registration therefor, in Canada, and all other marks
confusingly similar thereto, all variations of such marks, all members of any families of any of the foregoing marks, all designs and styles used by Transcept in the depiction of the foregoing marks and any copyrights therein, and all goodwill
appurtenant to any of the foregoing, that are owned or controlled by Transcept as of the NDA Transfer Date, in all respects free and clear of any and all liens, hypothecations, mortgages, charges, security interests, pledges and other encumbrances
and claims of any nature. In connection with the foregoing, on the date the assignment of said trademark(s) occurs, Transcept shall take all reasonable actions and execute all documentation 
  
  
 [***] Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from this exhibit and have been filed separately with the Securities and Exchange Commission.

  

 2 

 necessary to effect such assignment, including an Assignment of Trademark, substantially in the form of
assignment attached hereto as Exhibit B and suitable for recordation with the Canadian Intellectual Property Office and/or any other applicable governmental or regulatory authority in Canada and thereafter shall take all reasonable actions
requested by Clover to perfect Clover’s rights in the assigned trademark(s) throughout Canada at the expense of Clover, including the execution and delivery of any additional documents of assignment. 
 5) In order to provide a reasonable period for Clover to evaluate and for the parties to reach a definitive agreement in respect of the Proposed
Transaction, the parties agree that during the Option Period, unless Clover shall have notified Transcept in writing that it has decided not to pursue the Proposed Transaction, neither Transcept nor any of its affiliates, or any of its or their
respective directors, officers, employees, financial advisors or counsel, agents or representatives or any other party retained or engaged by Transcept or any affiliate of Transcept to assist in the analysis, the arranging, brokering, financing,
negotiation or consummation of the Proposed Transaction at any time will (either directly or through any intermediary) solicit, entertain offers or bids from, respond to, negotiate with or consider any offer, bid or proposal of any other person for
a transaction that would conflict with or impede the Proposed Transaction in any respect, or provide any non-public information to any third party in connection with such an offer, bid or proposal. Nothing herein shall preclude Transcept from
responding to inquiries from prospective licensees regarding the Proposed Transaction by informing such prospective licensees that Transcept is contractually prohibited from negotiating or granting licenses to Intermezzo® in Canada. 

6) Except as otherwise agreed between the parties, during the period from the date hereof until the earlier of (i) the expiration or termination of
the Option Period and (ii) the date on which Clover provides Transcept with written notice that negotiations towards a definitive agreement are terminated, Transcept will (a) reasonably cooperate with Clover to provide access to Clover of
Transcept’s books and records, and all other relevant documents and data, in each case, to the extent related to the Proposed Transaction, (b) prepare, file, prosecute and maintain all of its patents related to the Intermezzo® product
in Canada, and (c) keep Clover informed, in a timely manner, of material communications, notifications or other information which it receives or provides (directly or indirectly) with respect to the Intermezzo® product or related patents
and intellectual property with any regulatory authority in Canada, including, without limitation, the Canadian Intellectual Property Office, Health Canada and the Patent Medicines Price Review Board. Notwithstanding the foregoing subsections
(b) and (c) above, Transcept agrees that it shall not, during the Option Period, develop Intermezzo® for Canada or contact any regulatory authority in Canada regarding Intermezzo® without obtaining Clover’s prior written
consent; provided, however, Transcept shall be permitted to undertake and perform development work in Canada solely in connection with Transcept seeking regulatory approval for Intermezzo® anywhere in the world other than in Canada
(subject to any restrictions imposed by other written agreements between Transcept and Clover or its affiliates). 
 7) Except as and to the
extent required by law, without the prior written consent of the other party, neither Clover nor Transcept will, and each will direct and cause its officers, directors, employees, attorneys, accountants and other agents and representatives not to,
directly or indirectly, make any public comment, statement or communication with respect to, or otherwise publicly disclose or permit the public disclosure of this letter agreement or any of the terms, 
  

 3 

 conditions or other aspects of the Proposed Transaction between the parties. If a party is required by law
to make any such disclosure, it shall first provide to the other party the content of the proposed disclosure, the reasons such disclosure is required by law and the time and place the disclosure will be made and the opportunity to consult with
respect thereto. Disclosure shall be made only of that part of information that counsel advises that the party is legally required to disclose. All disclosures are subject to the terms of the Confidentiality Agreement (as defined in paragraph 10).

 8) Transcept represents and warrants that Transcept has not and will not incur any liability in connection with the Proposed Transaction to
any third party with whom Transcept has had discussions regarding any other transaction or the Proposed Transaction, and Transcept shall indemnify and hold harmless Clover and its affiliates and any of their respective successors and assigns from
any and all such claims. 
 9) Each party will be responsible for and bear all of its own fees and expenses (including any broker’s or
finder’s fees and the fees and expenses of its attorneys and other advisors) incurred at any time in connection with pursuing or consummating the Proposed Transaction. 
 10) Except for the Confidentiality Agreement, dated July 31, 2009, by and between Transcept and Mundipharma International Corporation Limited, an affiliate of Clover (the “Confidentiality
Agreement”), the provisions of this letter agreement constitute the entire agreement between the parties and supersede all prior oral or written agreements, understandings, representations and warranties and courses of conduct or dealings
between the parties on the subject matter set forth herein. The provisions of this letter agreement may only be amended or modified by a writing executed by each of the parties. This letter agreement will be governed by and construed under the laws
of the State of New York, without regard to conflict of laws principles. This letter agreement may be executed in one or more counterparts, each of which will be deemed to be an original and all of which, taken together, will constitute one and the
same agreement. This letter agreement will be binding on each party’s successors or assigns. Any successor of a party or assignee of a party’s rights and/or obligations hereunder will expressly assume performance of such rights and/or
obligations. 
 11) Neither party will be obligated to proceed with the Proposed Transaction unless and until it is approved by both
parties’ respective boards of directors and a definitive transaction agreement is signed, it being the express intent of the parties hereto that neither party shall be bound in the absence of such board approvals and such definitive agreement.
Neither party will have any obligation of any sort under this letter agreement or in connection with the Proposed Transaction except (i) as may be agreed in writing by the parties hereafter in a definitive transaction agreement and (ii) as
provided explicitly in this letter agreement (the “Binding Obligations”). In all other respects, this letter will not bind any party to enter into the Proposed Transaction. Except as may be expressly provided in the Binding
Obligations, no past or future action, course of conduct or failure to act relating to the Proposed Transaction, or relating to the negotiation of, or the failure to negotiate, the terms of the Proposed Transaction will give rise to any obligation
or other liability on the part of the parties hereto. In the event the parties enter into a definitive agreement with respect to the Proposed Transaction, such agreement will supersede this letter agreement in all respects. In the event this letter
agreement is terminated 
  

 4 

 prior to entering into a definitive agreement relating to the Proposed Transaction, numbered paragraphs 7,
8, 9, 10 and 11 shall survive such termination. 
 [remainder of this page intentionally left blank]

  

 5 

 If the foregoing correctly sets forth our entire understanding, please sign and return the
enclosed copy of this letter agreement in the space provided below. 
  

			
	 Very truly yours,

	
	LP CLOVER LIMITED
		
	By:	 	 /s/ Douglas Docherty

		 	Name: Douglas Docherty
		 	Title: General Manager

  
  

			
	 Accepted and Agreed to:

	
	TRANSCEPT PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Glenn A. Oclassen

		 	Name: Glenn A. Oclassen
		 	Title: President

  

 6 

 EXHIBIT A 
 [Letterhead of affiliate of LP Clover Limited] 
  
 [            ], 20[    ] 
 Transcept Pharmaceuticals, Inc. 
 1003 W. Cutting
Blvd., Suite #110 
 Point Richmond, CA 94804 
 Dear [            ]: 
 The undersigned
hereby agrees that the territory of Canada is deemed to be a part of the “Transcept Territory” as that term is defined in the license and collaboration agreement in respect of Intermezzo® between Transcept and the undersigned. This
agreement shall be effective solely upon, and as of the date of, delivery of this letter to Transcept. 
  
  

			
	 Very truly yours,

	
	 [Affiliate of LP Clover Limited]

		
	By:	 	  

		 	Name:
		 	Title:

  

 7 

 EXHIBIT B 
 FORM OF ASSIGNMENT 
 Transcept Pharmaceuticals, Inc.,
a Delaware corporation having its principal offices at 1003 W. Cutting Blvd., Suite # 110, Pt. Richmond, California 94804 (“Transcept”), owning the entire ownership of the INTERMEZZOTM trademarks set forth on Schedule A
hereto, hereby, for good and valuable consideration received by Transcept, (a) confirms that it has sold and assigned, and does hereby sell and assign, to LP CLOVER LIMITED, a Bermuda corporation having a place of business at 14 Par La Ville
Place, 14 Par-La-Ville Road, P.O. Box HM 2332, Hamilton HM JX, Bermuda (“Clover”), its successors and assigns, the entire ownership interest in the INTERMEZZOTM trademarks set forth on Schedule A hereto and the goodwill
attached thereto, to be held and enjoyed by Clover, its successors, assigns, or other legal representatives, to the full end of the term thereof, as may be extended by law as fully and entirely as the same would have been held and enjoyed by
Transcept if this assignment and sale had not been made, including, but not limited to, the right to sue for past infringement, and (b) authorizes and requests the Canadian Intellectual Property Office and any other granting authority to issue
any trademark, and any extensions or Supplementary Protections, resulting from or based in whole upon said INTERMEZZOTM trademarks to Clover. 
  
  

			
	 TRANSCEPT PHARMACEUTICALS, INC.

		
	By:	 	  

		 	Name:
		 	Title:

  

 8Amendment #2 to Patheon Manufacturing Services Agreement

 Exhibit 10.4 
 AMENDMENT #2 TO 
 PATHEON MANUFACTURING SERVICES
AGREEMENT 
 This Amendment #2 (hereinafter referred to as this “Amendment”), dated as of the 29th day of
July, 2009 (the “Amendment Date”), is made by and between Patheon Inc., a corporation existing under the laws of Canada (“Patheon Canada”), Patheon Pharmaceuticals Inc., a corporation existing under the laws of
Delaware (hereinafter referred to as “Patheon”), and Pivot Acquisition, Inc., a Delaware corporation formerly known as Transcept Pharmaceuticals, Inc. (hereinafter referred to as “Client”) and a wholly-owned
subsidiary of Transcept Pharmaceuticals, Inc. (a publicly-traded Delaware corporation hereinafter referred to as “Transcept”). Patheon Canada, Patheon and Client are sometimes referred to herein individually as a
“Party” or collectively as the “Parties”. 
 WHEREAS, the Parties have entered into that
certain Manufacturing Services Agreement dated October 6, 2006, as amended on January 1, 2008, pursuant to which Patheon agreed to supply quantities of Products to Client in the Territory (the “MSA”); 
 WHEREAS, Transcept has entered into that certain United States License and Collaboration Agreement dated as of the date hereof with Purdue
Pharma L.P., a Delaware limited partnership having a place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431 (hereinafter referred to as “Purdue” and such agreement the “Collaboration
Agreement”), pursuant to which, among other matters, Transcept has granted Purdue exclusive rights with respect to the commercialization of Products solely in the United States; 
 WHEREAS, Patheon and Purdue desire to enter into an agreement setting forth the terms and conditions of Patheon’s manufacture and
supply of a Product for Purdue solely with respect to the United States (the “Purdue MSA”); 
 WHEREAS, Patheon
and Transcept desire to amend the MSA so that Purdue may enter into such agreement with Patheon solely with respect to the United States; 
 WHEREAS, Patheon and Transcept desire for Client to retain all rights under the MSA with respect to the Territory excluding the United States and its territories and possessions; and 
 WHEREAS, the rights granted by Transcept to Purdue under the Collaboration Agreement do not come into effect until such time as the approved
NDA for a Product is transferred to Purdue pursuant to Section 4.2(c) of the Collaboration Agreement (hereinafter referred to as the “NDA Transfer”). 
 NOW, THEREFORE, the Parties agree as follows: 
 1. Capitalized Terms. All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them in the MSA. 

 2. Effective Date. This Amendment shall be effective as of the Effective Date. As
used herein, “Effective Date” means the date of Patheon’s deemed receipt (in accordance with Section 13.9 of the MSA) of the written notice from Transcept to Patheon pursuant to which Transcept notifies Patheon that the
NDA Transfer has occurred, such notice to be substantially in the form attached hereto as Exhibit A. 
 3.
Territory. Effective as of the Effective Date, the defined term “Territory” in Section 1.1 of the MSA shall be deleted in its entirety and amended as follows: 
 “Territory” means worldwide, except for the United States and its territories and possessions. 
 Notwithstanding the foregoing, effective upon any termination of the Purdue MSA, any and all rights with respect to the United States and its territories
and possessions shall revert to Client and the United States and its territories and possessions shall be included in the Territory under the MSA. Client and Transcept shall not be liable for any acts or omissions of Purdue under any such Purdue MSA
or otherwise. 
 4. Miscellaneous. 
 (a) Entire Agreement. This Amendment constitutes the entire agreement among the Parties with respect to the amendment of the MSA, and supersedes all prior agreements and understandings, both
written and oral, among the Parties with respect to the amendment and addition of the same. 
 (b) No Further Amendment; No
Conflict. The MSA shall remain in full force and effect except solely to the extent modified by this Amendment. In the event of a conflict between the MSA and this Amendment, this Amendment shall control. 
 (c) Governing Law. This Amendment shall be construed and enforced in accordance with the laws of the State of New York and the laws
of the United States applicable therein, without regard to any conflicts-of-law principle that directs the application to another jurisdiction’s law. The Parties expressly agree that the UN Convention on Contracts for the International Sale of
Goods shall not apply to this Agreement. 
 (d) Counterparts. This Amendment may be executed in counterparts, each of
which shall be deemed an original, and all of which together shall constitute one instrument. 
  

 2 

 IN WITNESS WHEREOF, this Amendment has been executed by the Parties hereto as of the
Amendment Date. 
  

									
	 Patheon Inc.
	 		 	Pivot Acquisition, Inc.
					
	By:	 	 /s/ Robert L. Zinger
	 		 	 By:
	 	 /s/ Glenn A. Oclassen

					
	 Name:
	 	 Robert L. Zinger
	 		 	 Name:
	 	 Glenn A. Oclassen

					
	 Title:
	 	 Exec. Dir. Tech. Svcs. and Bus. Mgt. N.D.
	 		 		 	 CEO and President

				
	 Patheon Pharmaceuticals Inc.
	 		 		 	
					
	By:	 	 /s/ Francis P. McCone
	 		 		 	
					
	 Name:
	 	 Francis P. McCone
	 		 		 	
					
	 Title:
	 	 Secretary
	 		 		 	

  

 3 

 Exhibit A 
 NOTICE OF EFFECTIVE DATE 
                             , 2009 
 Patheon Inc. 
 4721 Emperor Blvd. 
 Suite 200 
 Durham, NC 27703 
 Attention: President, North America and Chief Commercial Officer 
 Patheon Pharmaceuticals Inc. 
 2110 East Galbraith Road 
 Cincinnati, Ohio 45237-1625 
 Attention: Director of
Legal Services 
  

	 	Re:	Manufacturing Services Agreement between Patheon Inc., Patheon Pharmaceuticals Inc. and Pivot Acquisition, Inc., dated October 6, 2006, as amended on
January 1, 2008 and July 29, 2009. 

 Pursuant to the terms and conditions of the Manufacturing Services Agreement
between Patheon Inc. (“Patheon Canada”), Patheon Pharmaceuticals Inc. (“Patheon”) and Pivot Acquisition, Inc., dated October 6, 2006, as amended on January 1, 2008 and July 29, 2009 (the
“Agreement”) this letter serves as written notice from Transcept Pharmaceuticals, Inc. to Patheon Canada and Patheon that the NDA Transfer (as defined in Amendment #2 of the Agreement) has occurred. 
 Regards, 
 Transcept Pharmaceuticals, Inc.

 Name:                                      
                        
 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]